Molecular staging of node negative patients with colorectal cancer

Journal of Cancer

Volumn 4, Issue 3, 2013, Pages 193-199

  Hyslop, Terry ^a   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cancer biomarkers; Colorectal cancer; Early detection; Guanylyl cyclase C; Molecular stage

Indexed keywords

FLUOROURACIL; GUANYLATE CYCLASE; IRINOTECAN; OXALIPLATIN; TUMOR MARKER;

CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; INTESTINE EPITHELIUM CELL; LYMPH NODE METASTASIS; MOLECULAR DIAGNOSIS; PROTEIN EXPRESSION; RACE DIFFERENCE; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR CELL;

EID: 84882994084     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.5830     Document Type: Review

References (49)

1. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004; 54: 295-308. doi:54/6/295 [pii].
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010; 375: 1030-47.
3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2009.
4. Iddings D, Ahmad A, Elashoff D, Bilchik A. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol. 2006; 13: 1386-92. doi:10.1245/s10434-006-9120-y.
5. Nicastri DG, Doucette JT, Godfrey TE, Hughes SJ. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J Mol Diagn. 2007; 9: 563-71. doi:jmoldx.2007.070032 [pii]10.2353/jmoldx.2007.070032.
6. Chien C, Morimoto LM, Tom J, Li CI. Differences in colorectal carcinoma stage and survival by race and ethnicity. Cancer. 2005; 104: 629-39. doi:10.1002/cncr.21204.
7. Le H, Ziogas A, Lipkin SM, Zell JA. Effects of socioeconomic status and treatment disparities in colorectal cancer survival. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1950-62. doi:17/8/1950 [pii]10.1158/1055-9965.EPI-07-2774.
8. Marcella S, Miller JE. Racial differences in colorectal cancer mortality. The importance of stage and socioeconomic status. J Clin Epidemiol. 2001; 54: 359-66. doi:S0895-4356(00)00316-4 [pii].
9. Soneji S, Iyer SS, Armstrong K, Asch DA. Racial disparities in stage-specific colorectal cancer mortality: 1960-2005. Am J Public Health. 2010; 100: 1912-6.
10. Grothey A Does stage II colorectal cancer need to be redefined? Clin Cancer Res. 2011; 17: 3053-5.
11. Waldman SA, Hyslop T, Schulz S, Barkun A, Nielsen K, Haaf J, et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA. 2009; 301: 745-52. doi:301/7/745 [pii]10.1001/jama.2009.141.
12. Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. Cancer. 2012;118(9):2532-40.
13. Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clin Cancer Res. 2011; 17: 3293-303.
14. Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. J Surg Oncol. 2012; 106: 24-30.
15. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-36.
16. Ratto C, Sofo L, Ippoliti M, Merico M, Bossola M, Vecchio FM, et al. Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis Colon Rectum. 1999; 42: 143-54.
17. Radel C, Martus P, Papadoupolos T, Fazesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. Journal of Clinical Oncology. 2005; 23: 8688-96. doi:10.1200/jco.2005.02.1329.
18. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005; 352: 476-87. doi:352/5/476 [pii]10.1056/NEJMra040958
19. Benson AB, 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004; 22: 3408-19. doi:10.1200/JCO.2004.05.063JCO.2004.05.063 [pii].
20. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am. 2005; 89: 771-93. doi:S0025-7125(05)00024-6 [pii]10.1016/j.mcna.2005.03.001.
21. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol. 2006; 24: 2179-87.
22. Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Bresalier R, Lamerato LE, et al. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst. 2010; 102: 538-46.
23. Mayberry RM, Coates RJ, Hill HA, Click LA, Chen VW, Austin DF, et al. Determinants of black/white differences in colon cancer survival. J Natl Cancer Inst. 1995; 87: 1686-93.
24. White A, Vernon SW, Franzini L, Du XL. Racial disparities in colorectal cancer survival: to what extent are racial disparities explained by differences in treatment, tumor characteristics, or hospital characteristics? Cancer. 2010; 116: 4622-31.
25. Chen VW, Fenoglio-Preiser CM, Wu XC, Coates RJ, Reynolds P, Wickerham DL, et al. Aggressiveness of colon carcinoma in blacks and whites. National Cancer Institute Black/White Cancer Survival Study Group. Cancer Epidemiol Biomarkers Prev. 1997; 6: 1087-93.
26. Bilchik AJ, Hoon DS, Saha S, Turner RR, Wiese D, DiNome M, et al. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg. 2007; 246: 568-75.
27. Cagir B, Gelmann A, Park J, Fava T, Tankelevitch A, Bittner EW, et al. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med. 1999; 131: 805-12.
28. Iddings D, Bilchik A. The biologic significance of micrometastatic disease and sentinel lymph node technology on colorectal cancer. J Surg Oncol. 2007; 96: 671-7. doi:10.1002/jso.20918.
29. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med. 1998; 339: 223-8.
30. Carrithers SL, Barber MT, Biswas S, Parkinson SJ, Park PK, Goldstein SD, et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci U S A. 1996; 93: 14827-32.
31. Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn. 2005; 5: 701-13.
32. Pitari GM, Li P, Lin JE, Zuzga D, Gibbons AV, Snook AE, et al. The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther. 2007; 82: 441-7.
33. Waldman SA, Cagir B, Rakinic J, Fry RD, Goldstein SD, Isenberg G, et al. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis Colon Rectum. 1998; 41: 310-5.
34. Chervoneva I, Hyslop T, Iglewicz B, Johns L, Wolfe HR, Schulz S, et al. Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction. Anal Biochem. 2006; 348: 198-208. doi:S0003-2697(05)00776-1 [pii]10.1016/j.ab.2005.10.042.
35. Schulz S, Hyslop T, Haaf J, Bonaccorso C, Nielsen K, Witek ME, et al. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res. 2006; 12: 4545-52.
36. Chervoneva I, Li Y, Iglewicz B, Waldman S, Hyslop T. Relative quantification based on logistic models for individual polymerase chain reactions. Stat Med. 2007; 26: 5596-611. doi:10.1002/sim.3127.
37. Beaulieu M, Desaulniers M, Bertrand N, Deschesnes RG, Beaudry G, Garon G, et al. Analytical performance of a qRT-PCR assay to detect guanylyl cyclase C in FFPE lymph nodes of patients with colon cancer. Diagn Mol Pathol. 2010; 19: 20-7.
38. Haince JF, Houde M, Beaudry G, L'Esperance S, Garon G, Desaulniers M, et al. Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. J Clin Pathol. 2010; 63: 530-7.
39. Sargent DJ, Resnick MB, Meyers MO, Goldar-Najafi A, Clancy T, Gill S, et al. Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis. Ann Surg Oncol. 2011 Nov;18(12):3261-70.
40. Croner RS, Peters A, Brueckl WM, Matzel KE, Klein-Hitpass L, Brabletz T, et al. Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. Cancer. 2005; 104: 395-404. doi:10.1002/cncr.21170.
41. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet. 2006; 38: 540-9. doi:ng1781 [pii]10.1038/ng1781.
42. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994; 331: 213-21.
43. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-26. doi:NEJMoa041588 [pii]10.1056/NEJMoa041588.
44. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004; 22: 1564-71. doi:10.1200/JCO.2004.08.186JCO.2004.08.186 [pii].
45. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27: 2091-6. doi:10.1200/jco.2009.21.9170.
46. Wilson C, Schulz S, Waldman S. Cancer biomarkers: Where medicine, business, and public policy intersect. Biotechnology Healthcare. 2007.
47. Wilson C, Schulz S, Waldman SA. Biomarker development, commercialization, and regulation: individualization of medicine lost in translation. Clin Pharmacol Ther. 2007; 81: 153-5. doi:6100088 [pii]10.1038/sj.clpt.6100088.
48. Holland C. FDA-cleared/approved molecular diagnostic tests. Association for Molecular Pathology; 2006.
49. Sun F, Breuning W, Uhl S, Ballard R, Tipton K, Schoelles K. Quality, regulation and clinical utility of laboratory-developed tests. Technology Assessment Report: AHRQ; 2009.